Tykerb - Dual Tyrosine Kinase Inhibitor for the Treatment of Solid Tumours
Key Data:
Drug (Brand/Generic)
Tykerb/Tyverb/Lapatinib ditosylate
Company/Licensee
GlaxoSmithKline
Therapy Class
TKI
Product Description
Dual-acting TKI that targets erbB1 and erbB2
Current Indication
Breast cancer
Market Sector
Oncology
Development Status
Approved US and Europe
